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Infl uence of novel oral anticoagulants on anticoagulation care 
management
Anticoagulation treatment was recently improved by the 
introduction of novel oral anticoagulants (NOACs). Using a 
combination of qualitative and quantitative methods, this 
study explores the eﬀ ects of the introduction of NOACs on 
anticoagulation care in Slovenia. Face-to-face interviews 
with key stakeholders revealed evolvement and challenges 
of anticoagulation care from diﬀ erent perspectives. Ob-
tained information was further explored through the analy-
sis of nationwide data of drug prescriptions and realization 
of health care services. Simplifi ed management of antico-
agulation treatment with NOACs and their high pene-
tration expanded the capacity of anticoagulation clinics, 
and consequentially the treated population increased by 
more than 50 % in the last 5 years. The main challenge con-
cerned the expenditures for medicines, which increased 
approximately 10 times in just a few years. At the same 
time, the anticoagulation clinics and their core organisa-
tion were not aﬀ ected, which is not expected to change, 
since they are vital in delivering high-quality care.
Keywords:  novel oral anticoagulants, health care manage-
ment, anticoagulation care
Anticoagulation treatment is indicated for several conditions, including prevention of 
stroke in atrial fi brillation, and for the treatment and prevention of recurrent deep venous 
thrombosis and pulmonary embolism (1, 2). Incidence of atrial fi brillation, the disease that 
most frequently requires anticoagulation treatment, is approximately 1.5–2 % in the develo-
ped world, which is expected to double in the next 50 years (3). The most convenient route 
of administration for medicines is oral application. Until recently, oral anticoagulation 
(OAC) treatment was limited to only a few drugs, all from the same group of vitamin K 
antagonists (VKAs) (1). Eﬀ ectiveness of VKAs has been consistently shown, but these 
drugs have some major disadvantages (4). Variable pharmacokinetics with many drug-
drug interactions and a narrow therapeutic window are the main limitations for their use. 
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with these drugs and comprised close monitoring through specialized anticoagulation 
clinics, self-monitoring and self-management (5, 6). However, in the last decade, new 
drugs, known as new (or non-vitamin K) oral anticoagulants (NOAC), with less complex 
management, were introduced as alternatives to VKAs (3). NOACs are administered in 
fi xed doses and do not require frequent monitoring, but awareness before oversimplifi ca-
tion of treatment with NOACs has been exposed (7, 8). Published cost-eﬀ ectiveness studies 
have justifi ed their steep price, mainly due to the complexity of current treatment with 
VKAs (9, 10). However, introduction of these pricey drugs in combination with many po-
tential users could have a substantial impact on budgets. Therefore, health care authorities 
were looking for eﬀ ective models to optimize their utilisation (11, 12). NOACs were also 
introduced in Slovenia, like in many other countries, but there are diﬀ erences between 
countries in the approach, activities, and reimbursement restrictions (11, 13). Availability 
of NOACs is likely to have aﬀ ected the traditional management of anticoagulation treat-
ment and consequentially its organisation. NOACs are more suitable for patients as well 
as more convenient for health professionals. The purpose of this study was to explore the 
eﬀ ects of the introduction of NOACs in Slovenia and to specify the expected challenges in 
the anticoagulation care management system.  
EXPERIMENTAL
Evolvement of anticoagulation care in Slovenia was explored by a combination of quali-
tative and quantitative methods. Semi-structured interviews with key stakeholders were 
conducted to identify challenges and obtain insights into major changes in anticoagulation 
care from diﬀ erent perspectives. The information provided was then objectivized and ex-
panded with nationwide data on the usage and costs of medicines and health care services.
Interviews
Semi-structured interviews were selected because they enable focused and in-depth 
exploration of topics. To ensure suitable coverage of topics from diﬀ erent perspectives, we 
purposely recruited participants among leading experts, doctors, nurses, and clinical 
pharmacists involved in routine clinical practice, persons responsible for managing anti-
coagulation clinics, and representatives of public payers. We invited potential participants 
to obtain at least one opinion from each of the desired perspectives. The planned questions 
were open-ended and designed to permit interviewees to expand their answers, which 
could reveal new areas or ideas that were not anticipated. Six interviews with diﬀ erent 
respondents that consented to take part in the study were conducted on an individual 
basis at their respective workplaces. All interviews were conducted by one researcher (AJ) 
in July 2016. The interviews lasted approximately 30 minutes and were audio recorded. 
The transcripts were coded using standard thematic analysis techniques. The themes that 
emerged, highlighted from diﬀ erent perspectives, were classifi ed into categories and ad-
ditionally explored through analyses of health claims and health care services databases.
Databases
Data were extracted from two databases: the health claims data on prescription drugs 
and the data of realization of health care services. Both data sets were obtained from the 
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Health Insurance Institute of Slovenia (ZZZS), the public institute mandated to provide 
compulsory health insurance in Slovenia. The period from the introduction of the fi rst 
NOAC to the latest available data, namely from 2009 to the end of 2015, was analysed. 
The health claims database contains information on all outpatient medications dis-
pensed in Slovenia at the individual prescription level. In addition to information on the 
kind of medications, their quantity, and when they were dispensed, the database also 
contains basic information about the patients, such as age, sex, place of residence and in-
formation about the prescribers. The database of the realization of health care services 
contains information about the number of visits, type and amount of services delivered, 
number of staﬀ  and the value of services provided at the health care provider level.
Health claims database 
The health claims database was used to estimate the number of patients taking OACs, 
their basic characteristics, including concomitant treatments, the year they began antico-
agulation therapy, and the brand of their fi rst OAC, as well as the consumption of each 
individual drug for the analysis of volume and value. The selection of drugs was based on 
their anatomical therapeutic chemical (ATC) classifi cation; the whole group of VKAs (ATC 
code: B01AA), dabigatran etexilate (B01AE07), rivaroxaban (B01AF01), and apixaban 
(B01AF02) were considered. To estimate the number of patients treated with OACs, includ-
ing the number of initiating patients and the number starting the drugs each year, the 
criterion of the fi rst dispensed OAC was applied for all years. Possible switches of therapy 
within a year were not considered for this purpose. For the volume and value analysis, the 
consumption of all dispensed medicines was included. Defi ned daily dose (DDD) was 
selected as the measure of volume consumption.
Provision of health care services 
The database of the realization of health care services was used to evaluate the per-
formance and patient load of anticoagulation clinics and to estimate the economic burden 
of anticoagulation care. The number of visits, number of staﬀ  teams and the value of ser-
vices were extracted for each anticoagulation clinic at the primary level. The services of 
anticoagulation treatment at the secondary and tertiary levels were not recorded sepa-
rately, but as a part of specialized cardiology clinics, which also performed other services 
not related to anticoagulation. The loads of these clinics were estimated according to the 
total number of patients on anticoagulation treatment (extracted from the fi rst database) 
and the proportion of visits at the primary care level, estimated by experts. The absolute 
number of visits served to estimate the cost of anticoagulation treatment at the secondary 
and tertiary levels. 
RESULTS AND DISCUSSION
Qualitative research exposed seven themes, which were classifi ed into three catego-
ries: treated population, medicines, and organisation of anticoagulation care (Fig. 1). All 
except one (re-organisation of the work process) were also appropriate for the data analy-
sis and objectifi cation of respondents’ observations. 
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Population
Many stakeholders anticipated the growth of treated population, but it seems that the 
extent of the increase was not expected. Moreover, respondents also expect that this trend 
will continue and will represent the main challenge in coming years, as more patients 
request an increase in the capacity of health care services, which, in combination with 
higher consumption of medicines, is refl ected in expansion of the economic burden. Sev-
eral reasons were noted, most oft en they were ageing of the population, a higher diagnos-
tic rate, a more user-friendly therapy, and the diﬀ erent treatment approach, which also 
extends the eligibility of patients for anticoagulation treatment. As one respondent noted,
‘Some patients that should have been treated with oral anticoagulants were not treated in the 
past because of the challenges of VKA therapy, but now they can be treated with NOACs.’
Under-usage of oral anticoagulants in the pre- and early-NOAC era was also reported 
in other developed countries and availability of NOACs reduced the undertreated popula-
tion (14, 15). Similar observations were also recorded in our study, as data analysis revealed 
that the treated population increased from an average of 7.4 % per year to almost 55.000 in 
2015 (Table I). Based on the trends from 2012 to 2015, approximately 68,000 patients will be 
prescribed at least one OAC in 2018. Part of the reason for such increase could also be 
found in the broad policy of prescribing NOACs, which are available for naïve patients and 
patients with poor anticoagulation control on warfarin, but all patients should still be 
monitored at anticoagulation clinics. Simplifi ed management of treatment with NOACs 
released the capacity of anticoagulation clinics, which are now able to treat more patients. 
A representative statement is the following:
‘Our wide policy of prescribing NOACs enabled more patients to be properly treated and prob-
ably fewer complications occur. Without the availability of NOACs we would not be able to treat so 
many more patients, since we were already overloaded.’
Fig 1. The themes identifi ed in interviews and their categories. 
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The analysis of data showed that the majority of patients had already initiated antico-
agulation treatment with NOAC (74 % in 2015). Many educational activities for practitio-
ners were oﬀ ered when NOACs were introduced. The respondents were confi dent that the 
majority of prescribers followed clinical guidelines and complied with prescription limita-
tions. They perceived that the majority of patients with poor anticoagulation control were 
already translated to NOACs, and therefore, the number of patients on VKAs will probably 
remain stable, while the number of patients receiving NOACs will continue to rise. These 
observations were supported by data analysis, which revealed that the number of patients 
receiving VKAs increased up to 2012, and then declined by 3.4 % per year when NOACs 
became available for long-term treatment. At the same time, the number of patients receiv-
ing NOACs rapidly increased to almost 19,000 patients in 2015, accounting for 34 % of all 
patients receiving an OAC. High penetration of NOACs and their premium price raise the 
question of fi nancial sustainability. 
Table I. Characteristics of patients who received at least one oral anticoagulant
   2009 2010 2011 2012 2013 2014 2015
Number of patients (prevalence) 35,152 37,146 40,036 43,068 46,707 50,287 54,576
Average age (years) 72.5 72.6 72.7 73.1 73.4 73.8 74.0
Sex (% female) 51.3 51.4 51.4 51.5 51.3 51.6 51.4
Concomitant medicines (% of patients)        
 Blood pressure modifying agents (ATCs: C03, C07, C08, C09) 90.6 90.2 89.7 90 89.9 90.1 89.8
 Drugs used in diabetes (ATC: A10) 17.2 18.0 18.3 18.6 18.6 18.9 19.0
 Acetylsalicylic acid, low dose (ATC: B01AC06) 15.8 16.7 17.3 18.3 17.9 17.4 16.9
 Other oral antithrombotic agentsa   1.5   1.6   1.7   1.8   1.8   1.9   2.0
Number of patients received        
 VKA 34,618 35,675 37,715 39,722 38,664 37,199 35,812
 NOAC 534   1,471   2,321   3,346   8,043 13,088 18,764
  High doseb   0   0   0 359   2,659   5,526   8,571
  Moderate doseb 230 360 547 962   3,185   5,453   7,778
  Low doseb 304   1,111   1,774   2,025   2,199   2,109   2,415
Number of new patients (incidence)    8,423   9,371   9,904 10,695 11,377 12,308
 % receive VKA as fi rst OAC  83.3 77.4 70.4 42.1 34.6 26.4
VKA – vitamin K antagonist (warfarin, acenocoumarol), NOAC – non-vitamin K oral anticoagulant, OAC – oral 
anticoagulant
a Clopidogrel (ATC: B01AC04), plasugel (ATC: B01AC22), tricagrecol (ATC: B01AC24).
b High dose: dabigatran 150 mg, rivaroxaban 20 mg, apixaban 5 mg; moderate dose: dabigatran 110 mg, rivaroxaban 
15 mg, apixaban 2.5 mg; low dose: dabigatran 75 mg, rivaroxaban 10 mg.
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Medicines
Total expenditures for NOACs in 2015 were 8.2 million EUR, which is almost twice the 
entire budget for anticoagulation care before introduction of NOACs, including drug and 
monitoring costs. Compared to the traditional therapy, the volume consumption in 2015 
was comparable between NOACs and VKAs (6.7 million vs. 6.6 million DDDs), while ex-
penditures were approximately 10 times higher (Fig. 2). If the same trend should continue 
in the next 3 to 4 years, the economic burden of NOACs would probably exceed 15 million 
EUR. However, at the time of introduction some expected that expenditures for antico-
agulation clinics would substantially decline, but in fact they did not change signifi cantly. 
Most probably because the amount of work was not reduced, as new patients appeared. 
Most participants were aware that NOACs are much more expensive than warfarin and 
that consumption of these expensive drugs has risen rapidly, but they were not aware of 
the specifi cs at the national level. On the one hand, the practitioners said that they did not 
consider the economic aspect when deciding on an appropriate treatment; their decision 
was based solely on clinical criteria, taking into account reimbursement limitations. On 
the other hand, the same doctors also expressed concerns about potentially tighter pre-
scription limitations due to high expenditures. However, public payers are convinced that 
expenditures for NOACs are manageable and current aﬀ ordability can be maintained 
without imposing prescription limitations: 
Fig. 2. Yearly consumption (bars) in defi ned daily doses (DDDs) and expenses (lines) in EUR of oral 
anticoagulants.
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‘In this fi eld we have complex agreements with ample protection against uncontrolled growth 
of expenditures with all manufacturers. If we are able to maintain these agreements, the expenditures 
will rise, but in a manageable range, and there would not be a need to interfere.’
The prescribers claim that they do not prefer any specifi c medicine because each medi-
cine has its own characteristics. One medicine is sometimes suitable for one patient, some-
times for another. The nationwide data indicate a slightly higher growth of rivaroxaban 
compared to dabigatran etexilat, especially in later years. The underlying reason for this 
diﬀ erence does not appear to be the price, since all NOACs have nearly the same daily cost. 
However, a diﬀ erence between substances in the dispensed dosage was recorded. Most of 
rivaroxaban consumption was in a high dose (20 mg), while half of dabigatran etexilat 
consumption was in a moderate dose. 
Services
Many interviewees expected that the introduction of NOACs would reduce the bur-
den of already overloaded anticoagulation clinics. The practitioners have not observed the 
expected relief yet: 
‘You should know that our team manages 150 to 160 regular patients per day, and an addi-
tional up to 10 unplanned patients, who come to our clinic. Despite the fact that we try to refer a lot 
of patients to the primary level, the numbers are still enormous.’ 
Respondents also said that communication and collaboration between diﬀ erent levels 
were not as good as they should be. Some practitioners at the secondary level estimated 
that around 40 % of patients currently treated in their clinics could be managed at the 
primary level, but they cannot be transferred because of the insuﬃ  cient capacity at the 
primary level. This was confi rmed by data analysis (Table II). For example, in 2014 there 
were on average 24,169 visits per team at the primary level, which is 17 % more than the 
Table II. Performance and expenditures of anticoagulation clinics at the primary level and estimations for the 
secondary/tertiary level of health care
Year











2009 10 173 1.8 313–382 3.2–3.9
2010 10 212 1.9 292–363 2.6–3.3
2011 10 223 2.0 312–388 2.8–3.5
2012 11 245 2.1 322–401 2.8–3.5
2013 11 258 2.2 307–384 2.6–3.2
2014 11 264 2.2 296–371 2.5–3.1
2015 15 278 2.4 280–351 2.4–3.0
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norm set in the calculation of service value, which predicts 20,735 visits per team per year. 
In Slovenia, specialized anticoagulation clinics were introduced approximately a decade 
ago, but the network at the primary level is still being built, therefore there are some dif-
ferences between regions. This was also expressed by some interviewers:
‘In 2015 we fi nally got some necessary anticoagulation clinics at the primary level in our re-
gion. Prior to that, we had only a few private practitioners, who provided anticoagulation treatment 
to a limited extent.’
 ‘We do not expect that more patients will be referred to primary care unless something special, 
which is not expected, happens.’
Establishment of four anticoagulation clinics at the primary level, fi nanced by ZZZS 
as early as in 2015, should reduce the overload and more patients could be managed at the 
primary level. However, the question of expediency of further expansion of specialized 
clinics in the environment with high usage of NOACs naturally arises. Furthermore, some 
authors suggest that the role of anticoagulation clinics should be redefi ned, including as-
sisting patients and clinicians with selecting the appropriate anticoagulant and its dose, 
helping patients to minimize the bleeding risk, and potentially expanding their coverage 
to other higher risk medications (8). These activities will most probably be incorporated in 
the current work of anticoagulation clinics, but transferring current activities or only part 
of them to other facilities is not likely. This is mainly because stakeholders do not expect 
that this would have any important fi nancial impact and they are aware that high quality 
of care can be maintained only through specialised anticoagulation clinics:
‘Anticoagulation treatment is specifi c, requires special training and, most importantly, high 
frequency is necessary to ensure high-quality care.’
‘From the fi nancial point of view, I do not see any benefi t of shutt ing down anticoagulation 
clinics and relocating patients to other facilities; the number of visits would probably remain the 
same, fi nanced by the same payer at approximately the same price, so there would actually be no 
signifi cant fi nancial eﬀ ect.’
Nevertheless, these facilities will still be required for proper management of patients 
receiving VKAs, as these medications remain an important alternative to NOACs. Ap-
proximately one third of patients with atrial fi brillation are not eligible for treatment with 
NOACs, based on experts’ estimates confi rmed by database analysis. Lower demand for 
warfarin could raise the price, but this should not substantially aﬀ ect the economic burden 
of anticoagulation care, as the current price is approximately 30 times lower than NOACs.
The main strength of this study is that we combined epidemiologic data analysis with 
qualitative research. These two methods can complement each other. Qualitative research 
can provide the background or provide an additional perspective, justify reinterpretation 
of quantitative data, or serve as validating data. The major risk of the way we used these 
data arose from scarce or misleading information. We used high-quality databases but 
lacked data about the performance of clinics on the secondary and tertiary levels. Another 
limitation was that participants for interviews were purposely selected. Therefore, we 
cannot completely exclude bias in selection or the possibility that participants were not 
completely open with the researcher. Based on the att itude of respondents, however, we 
doubt that this problem occurred.
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CONCLUSIONS
 The introduction of NOACs into Slovenian medical practice enabled many more 
patients to be properly treated. First, patients that were not eligible for VKAs or manage-
ment of therapy was too complex for them now have access to appropriate treatment and 
thus bett er health prospects. Second, simplifi ed management of anticoagulation treatment 
with NOACs released some capacity of anticoagulation clinics, which was fi lled by new 
patients.  This was refl ected in the load of anticoagulation clinics, which did not diminish 
but slightly increased. Consequently, new anticoagulation clinics were established at the 
primary care level and strengthened their position in the health care system. In addition, 
the prevailing opinion is that such organisation assures high-quality care, including treat-
ment with NOACs. The fi nancial burden of anticoagulation treatment increased substan-
tially, but seems to be in a manageable range. More importantly, increased expenditures 
predict bett er health outcomes for the population, since more patients are properly treated. 
This would be diﬃ  cult to achieve without or with more limited access to NOACs, since 
there are limited resources for extension of the network of anticoagulation clinics. 
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